The primary function of this Core is to maintain cell lines and derived RNA for phenotyping studies by the PAAR investigators. The Core has created a total of 214 LCLs from sibling pair donors, and maintains 73 FCLs and 215 LCLs purchased from the Coriell cell repository. The latter were created from large families (CEPH/Utah). In compliance with Coriell policies (locus.umdnj.edu/ccr/comnVorder.html). Coriell cell cultures and DNA are not shared nor are they distributed. In contrast, cell lines, RNA and DNA from sibling pairs generated at UC are shared between institutions. The 214 cell lines from sibling donors include a number of ethnic groups: 51 European, 141 African American, 11 Hispanic, and 11 from other ethnic backgrounds, in contrast, the 215 cell lines from the CEPH collection are primarily European- Americans. The advantage to the CEPH collection is the publicly available genotypic information (landru.cephb.fr/cephdb/) and greater statistical power when using large pedigrees, whereas the advantage to the sibling pair collection is the collection of African Americans and Hispanics. FCLs are used for studies in cases where the expression levels of specific genes are higher relative to LCLs. The Cell Line Core is used by several Projects, Platforms, and Cores within PAAR. The Core is used by the CRC, CS, and CYP3A Projects; it interacts with the SDDA and Molecular Cores, and has provided DNA and RNA for the DR and WG Platforms.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01GM061393-09
Application #
7690744
Study Section
Special Emphasis Panel (ZRG1)
Project Start
Project End
Budget Start
2008-07-01
Budget End
2009-06-30
Support Year
9
Fiscal Year
2008
Total Cost
$75,248
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Zhou, Shuqin; Skaar, Debra J; Jacobson, Pamala A et al. (2018) Pharmacogenomics of Medications Commonly Used in the Intensive Care Unit. Front Pharmacol 9:1436
House, Larry; Seminerio, Michael J; Mirkov, Snezana et al. (2018) Metabolism of megestrol acetate in vitro and the role of oxidative metabolites. Xenobiotica 48:973-983
Gamazon, Eric R; Trendowski, Matthew R; Wen, Yujia et al. (2018) Gene and MicroRNA Perturbations of Cellular Response to Pemetrexed Implicate Biological Networks and Enable Imputation of Response in Lung Adenocarcinoma. Sci Rep 8:733
Li, M; Seiser, E L; Baldwin, R M et al. (2018) ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia. Pharmacogenomics J 18:35-42
Geeleher, Paul; Nath, Aritro; Wang, Fan et al. (2018) Cancer expression quantitative trait loci (eQTLs) can be determined from heterogeneous tumor gene expression data by modeling variation in tumor purity. Genome Biol 19:130
Wing, Claudia; Komatsu, Masaaki; Delaney, Shannon M et al. (2017) Application of stem cell derived neuronal cells to evaluate neurotoxic chemotherapy. Stem Cell Res 22:79-88
Rudin, Shoshana; Marable, Marcus; Huang, R Stephanie (2017) The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment. Genomics Proteomics Bioinformatics 15:82-93
Geeleher, Paul; Huang, R Stephanie (2017) Exploring the Link between the Germline and Somatic Genome in Cancer. Cancer Discov 7:354-355
Geeleher, Paul; Zhang, Zhenyu; Wang, Fan et al. (2017) Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies. Genome Res 27:1743-1751
Eadon, Michael T; Hause, Ronald J; Stark, Amy L et al. (2017) Genetic Variants Contributing to Colistin Cytotoxicity: Identification of TGIF1 and HOXD10 Using a Population Genomics Approach. Int J Mol Sci 18:

Showing the most recent 10 out of 372 publications